Tradestie Institutional Equity Comparison Engine

CDT vs ACAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CDT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ACAD at 15.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
CDT N/M vs ACAD 15.8x Fwd P/E
Growth & Margin Winner ACAD
Op Margin 0.0% vs 10.2% ยท YoY +0.0% vs +22.8%
Momentum & Technical Winner ACAD
1Y -86.8% vs -25.9% ยท 52W Pos 2% vs 8%
Options & Structure Winner ACAD
BREAKDOWN (N/A IV) vs BREAKDOWN (6th %ile IV)
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
1M Return -15.76%
1Y Return -25.93%
Forward P/E 15.8x
Unified AI Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CDT -86.78% ACAD -25.93% Spread: +60.85 pp (ACAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CDT TTM Op. Margin: 0.0% ACAD TTM Op. Margin: 10.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs ACAD. Trailing 12-month operating profitability (CDT 0.0% vs ACAD 10.2%) and valuation multiples (CDT N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CDT (0) vs ACAD (10)
Institutional Metric CDT ACAD Criterion Row Winner
Market Capitalization Scale $507,528 $3.0B Larger Scale ACAD
Trailing P/E Ratio Valuation N/M 8.3x Lower Multiple ACAD
Forward P/E Ratio Valuation N/M 15.8x Lower Multiple ACAD
Revenue Growth (YoY) Growth +0.0% +22.8% Higher Growth ACAD
Operating Margin (TTM) Profitability 0.0% 10.2% Higher Margin ACAD
Net Profit Margin Profitability 0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency -69.7% 31.4% Higher ROE ACAD
52-Week Range Position Momentum 2% ($0โ€“$11) 8% ($16โ€“$31) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime -17.75ฮฒ ยท 10175% Vol 0.15ฮฒ ยท 90% Vol Lower Realized Risk ACAD
Unified Institutional Score Composite Signal 31.6 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite ACAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CDT vs ACAD Buy Guide
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CDT nor ACAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.